Medpace celebrates first anniversary of Clinical Pharmacology Unit
Global clinical development firm Medpace, Inc. is celebrating the one-year anniversary of its Medpace Clinical Pharmacology Unit (CPU).The 30,000-square-foot, 63-bed facility utilizes all of the Medpace groups to conduct first-in-human and proof-of-concept studies in focused therapeutic areas such as diabetes, obesity, and hypertension.This past year, the CPU added Dr. Bernard Ilson to its team of experts, adding 21 years of experience in the pharmaceutical industry.Within its first year, the CPU has become an emerging industry leader in early phase studies and attracted top level scientific projects, including Phase I endocrinology and cardiology projects.Read the full article here.
Global clinical development firm Medpace, Inc. is celebrating the one-year anniversary of its Medpace Clinical Pharmacology Unit (CPU).
The 30,000-square-foot, 63-bed facility utilizes all of the Medpace groups to conduct first-in-human and proof-of-concept studies in focused therapeutic areas such as diabetes, obesity, and hypertension.
This past year, the CPU added Dr. Bernard Ilson to its team of experts, adding 21 years of experience in the pharmaceutical industry.
Within its first year, the CPU has become an emerging industry leader in early phase studies and attracted top level scientific projects, including Phase I endocrinology and cardiology projects.
Read the full article here.
Author
